You just read:

Quest PharmaTech's Subsidiary, OncoQuest, Signs Agreement with Shenzhen Hepalink Pharmaceutical Co., Ltd. to Fund Immunotherapy for Treatment of Cancer in China

News provided by

Quest PharmaTech Inc.

22 Mar, 2016, 09:30 ET